Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004

Bookmark and Share
Published: 22 Sep 2020
Views: 191
Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain

Dr Ana Arance spoke to ecancer about the LEAP 004 trial presented at the virtual ESMO 2020 meeting this year.

She initially outlined why levatinib and pembrolizumab can be used in combination for the treatment of advanced melanoma (MEL).

Dr Arance then went into some detail regarding the results of this trial and the efficacy of this treatment against MEL and safety profile was also discussed.

In the end, she discussed how the results from this trial can potentially change the clinical treatment of MEL and future studies that are required regarding this topic area of research.

Read related news here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.